Pancreatic cancer:: Factors regulating tumor development, maintenance and metastasis
Pancreatic cancer:: Factors regulating tumor development, maintenance and metastasis
复制标题
DOI：
10.1159/000055854
复制
发表时间：
2001-01-01
期刊：
影响因子：
3.6
通讯作者：
Büchler, MW
中科院分区：
文献类型：
--
作者：
Shi, X;Friess, H;Büchler, MW
胰腺癌是胃肠道恶性肿瘤中发病率最低的肿瘤之一。今天，它是西方工业化国家癌症相关死亡的第四或第五大原因，并且在过去几十年中发病率一直在增加。对生长抑制和凋亡信号的不敏感以及生长促进因子的自给自足是这种恶性肿瘤发病机制的标志。在胰腺癌中，多种生长因子及其受体以增加的水平表达。例如，表皮生长因子（EGF）受体及其配体EGF的伴随存在与增强的肿瘤侵袭性和肿瘤切除后较短的生存期相关。此外，许多其他生长因子及其受体，如神经生长因子及其受体，在胰腺癌中过表达，并导致其恶性表型。除了直接促进细胞增殖的因子外，多种其他因子如半乳糖凝集素被上调，这影响肿瘤环境和胰腺癌细胞的侵袭性。此外，肿瘤抑制基因如KAI1以降低的水平表达，从而增强胰腺细胞形成转移的能力。胰腺癌中存在复杂的因子干扰，导致明显的生长优势，这在临床上导致肿瘤快速进展和患者存活率低。版权所有（C）2001 S. Karger AG、巴塞尔和IAP。
Pancreatic cancer has one of the poorest prognoses of all gastrointestinal malignancies. Today, it is the fourth or, fifth leading cause of cancer-related deaths in Western industrialized countries, and the incidence has been increasing throughout the past decades. Insensitivity to growth-inhibitory and apoptotic signals as well as self-sufficiency of growth-promoting factors are hallmarks of the pathogenesis of this malignancy. In pancreatic cancer, a variety of growth factors and their receptors are expressed at increased levels. For example, the concomitant presence of the epidermal growth factor (EGF) receptor and its ligand EGF is associated with enhanced tumor aggressiveness and shorter survival following tumor resection. Furthermore, a number of other growth factors and their receptors, such as nerve growth factor and its receptor, are overexpressed in pancreatic cancer and contribute to its malignant phenotype. Besides factors which directly promote cell proliferation, a variety of other factors such as galectins are upregulated, which influences the tumor environment and the invasiveness of pancreatic cancer cells. In addition, tumor suppressor genes such as KAI1 are expressed at reduced levels, thereby enhancing the ability of pancreatic cells to form metastases. A complex disturbance of factors is present in pancreatic cancer, resulting in a distinct growth advantage which clinically results in rapid tumor progression and poor patient survival. Copyright (C) 2001 S. Karger AG, Basel and IAP.